Published in Int J Gynecol Cancer on May 01, 2012
Circulating microparticles: square the circle. BMC Cell Biol (2013) 1.14
Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform. Biomicrofluidics (2013) 0.95
Microparticles mediated cross-talk between tumoral and endothelial cells promote the constitution of a pro-metastatic vascular niche through Arf6 up regulation. Cancer Microenviron (2014) 0.87
N-Acetylcysteine Amide Protects Against Oxidative Stress-Induced Microparticle Release From Human Retinal Pigment Epithelial Cells. Invest Ophthalmol Vis Sci (2016) 0.82
An mDia2/ROCK signaling axis regulates invasive egress from epithelial ovarian cancer spheroids. PLoS One (2014) 0.81
VE-cadherin cleavage by ovarian cancer microparticles induces β-catenin phosphorylation in endothelial cells. Oncotarget (2016) 0.77
Lectin-Based Characterization of Vascular Cell Microparticle Glycocalyx. PLoS One (2015) 0.75
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 5.60
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Mining the plasma proteome for cancer biomarkers. Nature (2008) 4.10
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 3.99
Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest (2002) 3.90
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
A biomarker panel for acute graft-versus-host disease. Blood (2008) 3.83
Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol (2002) 3.63
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res (2013) 3.25
Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem (2002) 3.02
A compendium of potential biomarkers of pancreatic cancer. PLoS Med (2009) 3.00
Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol (2002) 2.72
Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol (2002) 2.71
Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol (2006) 2.66
Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol (2002) 2.44
Complementary structural information from a tryptic N-linked glycopeptide via electron transfer ion/ion reactions and collision-induced dissociation. J Proteome Res (2005) 2.44
Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol (2003) 2.38
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J (2007) 2.22
A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA (2008) 2.16
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer (2010) 2.13
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res (2007) 2.04
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn (2012) 1.99
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol (2003) 1.92
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A (2002) 1.89
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol (2011) 1.77
EphrinB2 reverse signaling protects against capillary rarefaction and fibrosis after kidney injury. J Am Soc Nephrol (2013) 1.77
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol (2009) 1.77
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol (2011) 1.74
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One (2008) 1.72
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res (2002) 1.60
Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics (2005) 1.59
Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol (2008) 1.55
Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer (2008) 1.53
Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol (2007) 1.49
SO2-* electron transfer ion/ion reactions with disulfide linked polypeptide ions. J Am Soc Mass Spectrom (2005) 1.48
Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells. J Clin Invest (2006) 1.47
Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer (2011) 1.47
Electron transfer versus proton transfer in gas-phase ion/ion reactions of polyprotonated peptides. J Am Chem Soc (2005) 1.47
Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res (2003) 1.46
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am J Obstet Gynecol (2012) 1.43
An evaluation of cervical cancer in women age sixty and over. Gynecol Oncol (2008) 1.43
ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity (2008) 1.43
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol (2004) 1.41
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res (2007) 1.40
Identification of novel alternative splice isoforms of circulating proteins in a mouse model of human pancreatic cancer. Cancer Res (2009) 1.40
Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res (2011) 1.37
The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis (2004) 1.31
Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood (2003) 1.30
Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer (2005) 1.28
Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res (2005) 1.27
Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila) (2009) 1.27
Modification of host lipid raft proteome upon hepatitis C virus replication. Mol Cell Proteomics (2006) 1.26
Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol (2012) 1.24
Phosphorylation site identification via ion trap tandem mass spectrometry of whole protein and peptide ions: bovine alpha-crystallin A chain. Anal Chem (2003) 1.24
Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res (2008) 1.22
A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics (2002) 1.22
Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med (2009) 1.21
In vivo and in vitro differentiation of myocytes from human bone marrow-derived multipotent progenitor cells. Exp Hematol (2003) 1.20
Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene (2003) 1.20
Direct isolation, culture and transplant of mouse skeletal muscle derived endothelial cells with angiogenic potential. PLoS One (2008) 1.19
Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One (2009) 1.17
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol (2008) 1.15
Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res (2009) 1.15
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) (2012) 1.15
A functional annotation of subproteomes in human plasma. Proteomics (2005) 1.15
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer (2012) 1.14
Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res (2011) 1.14
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer (2009) 1.12
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol (2006) 1.12
An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res (2004) 1.12
Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med (2012) 1.12